|
Name |
3-O-methylfunicone
|
Molecular Formula | C20H20O8 | |
IUPAC Name* |
methyl 3,5-dimethoxy-2-[5-methoxy-4-oxo-6-[(E)-prop-1-enyl]pyran-3-carbonyl]benzoate
|
|
SMILES |
C/C=C/C1=C(C(=O)C(=CO1)C(=O)C2=C(C=C(C=C2OC)OC)C(=O)OC)OC
|
|
InChI |
InChI=1S/C20H20O8/c1-6-7-14-19(26-4)18(22)13(10-28-14)17(21)16-12(20(23)27-5)8-11(24-2)9-15(16)25-3/h6-10H,1-5H3/b7-6+
|
|
InChIKey |
WGLRJONCGNNMKL-VOTSOKGWSA-N
|
|
Synonyms |
3-O-methylfunicone; CHEMBL3593571; Methyl 3,5-dimethoxy-2-[5-methoxy-4-oxo-6-[(E)-prop-1-enyl]pyran-3-carbonyl]benzoate; Methylfunicone; SCHEMBL902950; MEGxm0_000103; ACon0_000934; ACon1_000360; DTXSID801045493; BDBM50104668; ZINC31156764; Q15410219; NCGC00169150-03!methyl 3,5-dimethoxy-2-[5-methoxy-4-oxo-6-[(E)-prop-1-enyl]pyran-3-carbonyl]benzoate
|
|
CAS | NA | |
PubChem CID | 10548301 | |
ChEMBL ID | CHEMBL3593571 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 388.4 | ALogp: | 2.7 |
HBD: | 0 | HBA: | 8 |
Rotatable Bonds: | 8 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 97.4 | Aromatic Rings: | 2 |
Heavy Atoms: | 28 | QED Weighted: | 0.525 |
Caco-2 Permeability: | -4.624 | MDCK Permeability: | 0.00003540 |
Pgp-inhibitor: | 0.987 | Pgp-substrate: | 0.001 |
Human Intestinal Absorption (HIA): | 0.038 | 20% Bioavailability (F20%): | 0.037 |
30% Bioavailability (F30%): | 0.929 |
Blood-Brain-Barrier Penetration (BBB): | 0.228 | Plasma Protein Binding (PPB): | 74.25% |
Volume Distribution (VD): | 0.6 | Fu: | 17.59% |
CYP1A2-inhibitor: | 0.759 | CYP1A2-substrate: | 0.96 |
CYP2C19-inhibitor: | 0.815 | CYP2C19-substrate: | 0.346 |
CYP2C9-inhibitor: | 0.819 | CYP2C9-substrate: | 0.876 |
CYP2D6-inhibitor: | 0.269 | CYP2D6-substrate: | 0.833 |
CYP3A4-inhibitor: | 0.751 | CYP3A4-substrate: | 0.319 |
Clearance (CL): | 7.598 | Half-life (T1/2): | 0.588 |
hERG Blockers: | 0.02 | Human Hepatotoxicity (H-HT): | 0.522 |
Drug-inuced Liver Injury (DILI): | 0.934 | AMES Toxicity: | 0.11 |
Rat Oral Acute Toxicity: | 0.419 | Maximum Recommended Daily Dose: | 0.107 |
Skin Sensitization: | 0.258 | Carcinogencity: | 0.222 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.104 |
Respiratory Toxicity: | 0.526 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003039 | 0.817 | D09DHY | 0.322 | ||||
ENC003306 | 0.767 | D02LZB | 0.302 | ||||
ENC001897 | 0.709 | D0A8FB | 0.283 | ||||
ENC003307 | 0.596 | D06GCK | 0.283 | ||||
ENC005979 | 0.505 | D0G8NJ | 0.280 | ||||
ENC004340 | 0.486 | D0J4JM | 0.274 | ||||
ENC004806 | 0.474 | D01FFA | 0.271 | ||||
ENC005977 | 0.465 | D0C1SF | 0.270 | ||||
ENC005931 | 0.440 | D09HDR | 0.266 | ||||
ENC002468 | 0.430 | D0G4KG | 0.265 |